XELOX Combined With Sintilimab and HBO for Advanced or Metastatic GC/GEJC

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

57

Participants

Timeline

Start Date

December 31, 2024

Primary Completion Date

December 31, 2026

Study Completion Date

December 31, 2026

Conditions
Gastric (Stomach) Cancer
Interventions
DRUG

XELOX+Sintilimab+HBOT

"Patients will receive the XELOX regimen, consisting of oxaliplatin (130 mg/m² IV on Day 1) and capecitabine (1000 mg/m² orally twice daily for 14 days, repeated every 3 weeks), combined with sintilimab (200 mg IV on Day 1 every 3 weeks) and hyperbaric oxygen therapy (HBOT) administered alongside the XELOX regimen. Treatment will be administered for 4 to 6 cycles.~Following the initial treatment phase, patients will be evaluated for response. If disease progression is observed, patients will exit the study and receive subsequent treatments as deemed appropriate. For patients with stable disease or a response to therapy, maintenance treatment with capecitabine and sintilimab will continue until the occurrence of a study endpoint or other specified criteria."

Trial Locations (2)

610041

RECRUITING

West China Hospital of Sichuan University, Chengdu

NOT_YET_RECRUITING

West China Hospital, Sichuan University, Chengdu

All Listed Sponsors
lead

West China Hospital

OTHER